Tecentriq (Atezolizumab)
What is a Generic Drug?
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Coming Soon – Save up to 85%
Sign up to get exclusive coupon discounts and be the first to be notified when we have this product available.
Prescription Required
-
Product Details
Description
Tecentriq (Atezolizumab) is a monoclonal antibody medication used to treat various types of cancer, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), melanoma, and hepatocellular carcinoma. It works as a programmed cell death ligand 1 (PD-L1) blocking antibody. By blocking the interaction between PD-L1 and its receptors, Tecentriq allows immune cells to recognize and target cancer cells more effectively. It is supplied as an injectable solution.
Fact Table
Formula
C6446H9902N1706O1998S42
License
US DailyMed
Bioavailability
30%
Legal status
Rx-Only
Chemical Name
Atezolizumab
Elimination half-life
27 days
Dosage (Strength)
60mg/mL (14-mL or 20-mL single-dose vial)
Pregnancy
Atezolizumab is not recommended for use in pregnancy
Brands
Tecentriq
Protein binding
Unknown
PubChem SID
249565671
MedlinePlus
a616035
ChEBI
Not Assigned
ATC code
L01FF05
DrugBank
DB11595
KEGG
D10773
Routes of administration
Intravenous infusion
Directions
Tecentriq (Atezolizumab) is administered intravenously (IV). It is typically given in a clinic or hospital setting by a trained medical professional. The standard dosage is 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks. However, the dosage may vary depending on the cancer being treated. In addition, Tecentriq may be used in combination with other cancer treatments, such as bevacizumab, depending on the type and stage of cancer being treated. Always follow the directions provided by your healthcare team.
Ingredients
The active ingredient in Tecentriq is Atezolizumab.
Contraindications
There are no known contraindications for Tecentriq. However, it may be advised to avoid taking or using Tecentriq if you have a known allergy to Atezolizumab or any of its components.
Cautions
- Before starting Tecentriq, discuss the following with a healthcare provider:
- Medical conditions, including immune system problems, a history of an organ transplant, or nervous system conditions.
- Any medications you currently take.
- Whether you are pregnant or breastfeeding.
- Tecentriq might not be suitable for everyone. Individuals with a history of severe immune reactions or allergies to similar medications should inform their doctor before starting treatment.
- As an immune checkpoint inhibitor, Tecentriq can cause an overactive immune system, potentially leading to inflammatory reactions and organ damage. Inform your doctor immediately if you notice symptoms like fever, rash, joint pain, or unusual tiredness.
- Some people might experience infusion-related reactions, including fever, chills, shortness of breath, or chest pain during or after the administration of Tecentriq. Notify your healthcare provider immediately if you develop any of these symptoms.
- Let your doctor know if you’re experiencing symptoms like cough, abdominal pain, skin rash, or any other new changes that concern you. Your doctor will do some tests before you start Tecentriq and will keep checking your health during treatment.
- If you have had or are going to have a bone marrow transplant that uses stem cells from a donor (allogeneic HSCT), using Tecentriq could lead to severe complications, some of which could be life-threatening.
Side Effects
Tecentriq (Atezolizumab) may cause side effects in some people. Common side effects include cough, decreased appetite, fatigue, nausea, and shortness of breath. In addition, some people may experience body aches or pain, dizziness, fever, and frequent urge to urinate.
Tecentriq can also cause more serious side effects, which require immediate medical attention. These include lung problems, intestinal problems, liver problems, hormone gland problems, kidney problems, skin problems, and problems in other organs. There is also a risk of infusion reactions that can sometimes be severe or life-threatening. If you experience any serious side effects, seek medical advice as soon as possible.
References
- Tecentriq (Atezolizumab) Product Monograph. San Francisco, CA: Genentech, Inc; 2023.
- Tecentriq (Atezolizumab) Drug Label Information. South San Francisco, CA: Genentech, Inc.; 2023.
IMPORTANT NOTE: The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.Product Code : 14399
-
Product Reviews
